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Sphingosine kinase 2 activates autophagy and protects
neurons against ischemic injury through interaction
with Bcl-2 via its putative BH3 domain
Dan-Dan Song1,4, Tong-Tong Zhang1,4, Jia-Li Chen1, Yun-Fei Xia1, Zheng-Hong Qin1, Christian Waeber2,3 and Rui Sheng*,1
Our previous findings suggest that sphingosine kinase 2 (SPK2) mediates ischemic tolerance and autophagy in cerebral
preconditioning. The aim of this study was to determine by which mechanism SPK2 activates autophagy in neural cells. In both
primary murine cortical neurons and HT22 hippocampal neuronal cells, overexpression of SPK2 increased LC3II and enhanced the
autophagy flux. SPK2 overexpression protected cortical neurons against oxygen glucose deprivation (OGD) injury, as evidenced
by improvement of neuronal morphology, increased cell viability and reduced lactate dehydrogenase release. The inhibition of
autophagy effectively suppressed the neuroprotective effect of SPK2. SPK2 overexpression reduced the co-immunoprecipitation
of Beclin-1 and Bcl-2, while Beclin-1 knockdown inhibited SPK2-induced autophagy. Both co-immunoprecipitation and GST pull-
down analysis suggest that SPK2 directly interacts with Bcl-2. SPK2 might interact to Bcl-2 in the cytoplasm. Notably, an SPK2
mutant with L219A substitution in its putative BH3 domain was not able to activate autophagy. ATat peptide fused to an 18-amino
acid peptide encompassing the native, but not the L219A mutated BH3 domain of SPK2 activated autophagy in neural cells. The
Tat-SPK2 peptide also protected neurons against OGD injury through autophagy activation. These results suggest that SPK2
interacts with Bcl-2 via its BH3 domain, thereby dissociating it from Beclin-1 and activating autophagy. The observation that
Tat-SPK2 peptide designed from the BH3 domain of SPK2 activates autophagy and protects neural cells against OGD injury
suggest that this structure may provide the basis for a novel class of therapeutic agents against ischemic stroke.
Cell Death and Disease (2017) 8, e2912; doi:10.1038/cddis.2017.289; published online 6 July 2017
Sphingolipids, the major components in eukaryotic lipid
bilayers and prokaryotic cell membranes, play important roles
in cell survival and death.1 Sphingosine 1-phosphate (S1P)
promotes cell survival and proliferation, while ceramide and
sphingosine inhibit cell growth and induce cell apoptosis.2
Both isoforms of sphingosine kinases (SPK1 and SPK2)
catalyze the phosphorylation of sphingosine to S1P, thereby
controlling, together with S1P-degrading enzymes, the bal-
ance of sphingolipid species. SPK2 is likely to play a role in
various diseases, such as cancer,3,4 cardiovascular
diseases5,6 and inflammation.7–10 Recent studies also
demonstrate that SPK2 is involved in stroke, preconditioning
and neuronal autophagy11–13 and may be a potential
therapeutic target for the prevention and management of
cerebral ischemia. But the mechanistic link between SPK2
and preconditioning or neuroprotection remains to be defined.
Autophagy is a dynamic process in eukaryotic cells that
removes proteins or damaged organelles for recycling. In
neurons, the autophagosomes at different maturation states in
the cell soma are derived from distinct neuronal compart-
ments, possibly to facilitate autophagosome degradation by
fusion with lysosomes enriched in the soma. Surprisingly,
neither rapamycin, a traditional autophagy inducer, nor
nutrient deprivation induced neuronal autophagy as that in
non-neuronal cells. This may indicate that the primary role of
constitutive autophagy in neurons is to effectively turnover
aging proteins and organelles to maintain homeostasis, rather
than to mobilize amino acids under starvation.14 Autophagy
may contribute to the neuroprotection induced by ischemic,
hypoxic and isoflurane preconditioning (ISO).15–17 Various
sphingolipids, including ceramide and S1P, have been shown
to be involved in the regulation of autophagy.18 S1P produced
by SPK1 overexpression in cell lines activates autophagy,
possibly via suppression of mTOR activity and mild accumula-
tion of Beclin-1.19,20 Cytoplasmic S1P generated by SPK1
enhances autophagy flux in neurons,21 whereas the S1P
lyase, a kind of S1P-metabolizing enzyme, downregulates
autophagy.22 However, the contribution of SPK2 to autophagy
within neurons remains to be elucidated. Our previous findings
showed that the endogenous SPK2 isoform contributes to
autophagy activation induced by ISO and hypoxic
preconditioning.17 Interestingly, the SPK2 mediated autop-
hagy and protection seemed to be S1P-independent, but
possibly due to the disruption of Beclin-1/Bcl-2 interaction.17
SPK2 contains a 9-amino acid sequence similar to that seen in
pro-apoptotic BH3-only proteins; indeed, SPK2 induces
apoptosis in different cell types.23 BH3-only proteins such as
Bad and BNIP3 have been shown to mediate autophagy by
disrupting the interaction between Beclin-1 and Bcl-2 or
Bcl-XL.
24–26 We previously hypothesized that SPK2 might
1Department of Pharmacology and Laboratory of Aging and Nervous Diseases, Soochow University School of Pharmaceutical Science, Suzhou, China; 2Department of
Pharmacology and Therapeutics, University College Cork, Cork, Ireland and 3School of Pharmacy, University College Cork, Cork, Ireland
*Corresponding author: R Sheng, Department of Pharmacology and Laboratory of Aging and Nervous Diseases, Soochow University School of Pharmaceutical Science,
199 Ren Ai Road, Suzhou 215123, China. Tel/Fax: +86 512 65882071; E-mail: sheng_rui@163.com
4These authors contributed equally to this work.
Received 13.2.17; revised 26.5.17; accepted 29.5.17; Edited by GM Fimia
Citation: Cell Death and Disease (2017) 8, e2912; doi:10.1038/cddis.2017.289
Ofﬁcial journal of the Cell Death Differentiation Association
www.nature.com/cddis
similarly induce autophagy by interaction with Bcl-2 via its BH3
domain.17
In the present study, we directly examined the effect of
overexpressed SPK2 in primary cultured murine cortical
neurons and HT22 neuronal cells to test the hypothesis that
SPK2 could protect neural cells from ischemic injury by
activating autophagy. Next we explored the mechanisms
underlying autophagy activation induced by SPK2.
Results
SPK2 protects neurons from oxygen and glucose
deprivation injury. Neuronal and/or microvascular SPK2
have been shown to play a role in cerebral
preconditioning.11–13 To examine whether SPK2 can directly
protect against ischemic injury, we overexpressed SPK2 in
primary murine cortical neurons; lentivirus-mediated SPK2
overexpression in cortical neurons was monitored with GFP
immunofluorescence (Figure 1a). SPK2 and HA-Tag protein
overexpression was confirmed by western blot analysis
(Figures 1b and c). We also established a stable SPK2-
overexpressing cell line (LV-SPK2-HT22 cells) by infecting
HT22 cells with SPK2 lentivirus. SPK2, but not SPK1, was
upregulated in LV-SPK2-HT22 cells (Supplementary
Figure S1a), and the SPK2 activity significantly increased
compared with LV-vector-HT22 cells (Supplementary
Figure S1b). Cortical neuron cultures were then oxygen and
glucose deprived for 4 h (OGD). Cell viability and cytotoxicity
were determined using Cell Counting Kit-8 (CCK8) and
lactate dehydrogenase (LDH) assay kits, respectively. OGD
significantly decreased the viability and membrane integrity of
cortical neurons, whereas SPK2-overexpressing neurons
showed reduced cell death, as evidence by increased cell
viability (Figure 1d), reduced LDH leakage (Figure 1e) and
improved neuronal morphology (Figure 1f) compared with
neurons infected with LV-vector.
Overexpression of SPK2 induces autophagy activation.
To expand on our previous observation that SPK2 may protect
neurons through autophagy activation,17 we examined autop-
hagic activity in SPK2-overexpressing neurons. The LC3II was
increased after SPK2 overexpression compared with
LV-vector-infected neurons. OGD upregulated LC3II, in agree-
ment with published results,16,27–31 while SPK2 overexpres-
sion further increased LC3II after OGD treatment (Figure 2a).
We then examined the autophagic flux in SPK2-
overexpressing neurons using ammonium chloride (NH4Cl),
an inhibitor of lysosome-phagosome fusion.32,33 The LC3II/
actin ratio in the presence versus absence of NH4Cl increased
in SPK2-overexpressing neurons compared with vector-
infected neurons (Figure 2b), suggesting that overexpression
of SPK2 enhanced autophagic flux. Similar to the results in
cortical neurons, the LC3II in LV-SPK2-HT22 was much higher
than that in LV-vector-HT22 cells (Supplementary Figure S2a),
and SPK2 overexpression enhanced autophagy flux in
LV-SPK2-HT22 cells as well (Supplementary Figure S2b).
3-Methyladenine (3-MA) is a specific autophagy inhibitor that
blocks the formation of autophagosomes.34 Pretreatment with
3-MA at a concentration known to block autophagy
(10 mM)16,35,36 abolished the neuroprotection induced by
SPK2 overexpression, as evidenced by reduced cell viability
(Figure 2c) and increased LDH leakage (Figure 2d). All these
results suggest that SPK2 mediates autophagy activation and
contributes to the ischemic tolerance.
Overexpression of SPK2 interferes with the interaction of
Beclin-1 and Bcl-2. Beclin-1, the mammalian homolog of
yeast Apg6/Vps30, is a key regulator of autophagy.37 To test
the hypothesis that the autophagy activation by SPK2 involves
the Beclin-1 pathway, we examined the effect of siRNA-
mediated Beclin-1 knockdown on autophagic activity. In SPK2-
overexpressing neurons, Beclin-1 was effectively downregu-
lated by two different Beclin-1 siRNAs (Figure 3a). Treatment
with Beclin-1 siRNAs also markedly inhibited SPK2-induced
LC3II upregulation (Figure 3b), suggesting that SPK2 activates
autophagy in a Beclin-1-dependent manner. Beclin-1 interacts
with Bcl-2 via its BH3 domain,25,38 this interaction prevents
Beclin-1 from activating autophagy, and autophagy is initiated
when Beclin-1 is released from the Beclin-1/Bcl-2
complex.39,40 To confirm our previous hypothesis that SPK2
can interfere with the interaction between Beclin-1 and Bcl-2,17
we further examined the co-immunoprecipitation of Beclin-1
and Bcl-2 in cortical neuron lysates. Beclin-1/Bcl-2 co-
immunoprecipitation was reduced when SPK2 was over-
expressed in cortical neurons (Figure 3c), confirming that
SPK2 might disrupt the interaction between Beclin-1 and Bcl-
2, resulting in autophagy activation.
SPK2 interacts with Bcl-2. We then set out to test the
hypothesis that SPK2 induces autophagy by interacting with
Bcl-2 and examined the interaction of SPK2 and Bcl-2 by
co-immunoprecipitation and GST pull-down analysis in
lysates of SPK2-overexpressing HT22 cells. Bcl-2 was co-
immunoprecipitated when HA-SPK2 was immunoprecipitated
using HA antibodies, whereas Bcl-2 barely precipitated in cell
lysates in the absence of HA-SPK2 (Figure 4a). Correspond-
ingly, HA-SPK2 was co-immunoprecipitated when Bcl-2 was
precipitated (Figure 4b). The interaction of SPK2 with Bcl-2
was further assessed by in vitro pull-down experiments using
GST-Bcl-2 or GST alone bound to glutathione-agarose and
lysates of SPK2- or vector-infected HT22 cells. The data
demonstrated a specific interaction of SPK2 with GST-Bcl-2
but not with GST alone (Figure 4c). These results, taken
together with the fact that SPK2 dissociates the complex
between Beclin-1 and Bcl-2, further confirm that SPK2
interacts with Bcl-2 to release Beclin-1 from Beclin-1/Bcl-2
complex and to activate autophagy.
In neurons, SPK2 could be expressed in the cytoplasm,
mitochondria and nucleus under physiological or pathological
conditions.41–44 Our previous finding showed that precondi-
tioning mainly upregulates endogenous SPK2 in the cyto-
plasm. On the other hand, apoptosis-stimulating protein of
p53-2 (ASPP2) could bind to Bcl-2 in the nucleus to prevent its
translocation to the cytoplasm, thus contributing to Beclin-1-
initiated autophagy.45 We then examined the cellular distribu-
tion of SPK2 and whether Bcl-2 translocates to the nucleus
when SPK2 is overexpressed in neural cells. The immuno-
fluorescence (Figure 5a) and western blot analysis (Figure 5b)
showed that SPK2 was overexpressed in both the cytoplasm
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Figure 1 SPK2 overexpression protected primary cortical neurons from OGD injury. (a) Cortical neurons were infected with LV-SPK2 or LV-vector at DIV2. At DIV 7, the
neurons were visualized with bright field, and the efficiency of infection was detected by GFP fluorescence. Scale bar= 100 μm. (b and c) Overexpression of SPK2 was induced
by lentivirus gene infection. Neurons were harvested and subjected to western blot analysis against HA-tag (b) or SPK2 (c). (d) SPK2 protected cortical neurons from OGD injury.
Cortical neurons were exposed to OGD for 4 h. The cell viability was examined with Cell Counting Kit-8 assay. (e) Cytotoxicity was examined with LDH assay after OGD treatment
for 4 h. (f) The neuronal morphology was observed by optical microscope. Scale bar= 100 μm. Bar represents mean± S.D., n= 3 independent experiments. *Po0.05,
***Po0.001
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and nucleus of LV-SPK2-HT22 cells. In SPK2-overexpressing
neurons, however, although SPK2 was also overexpressed in
both cytoplasm and nucleus, its cytoplasmic content is much
higher than that in nuclear fraction (Figure 5c). Bcl-2 was
mainly expressed in the cytoplasm of both LV-SPK2-HT22
cells and SPK2-overexpressing neurons. There was no
significant nuclear translocation of Bcl-2 under SPK2 over-
expression. We also examined the cellular distribution of
endogenous SPK2 in neurons after ISO, a noxious stimulus
that could be applied conveniently to elicit neuroprotection
in vivo and in vitro.11 The results showed that SPK2 was
expressed in both cytoplasm and nucleus of control neurons.
After ISO treatment, SPK2 was upregulated in the cytoplasm
instead of nucleus (Figure 5d), consistent with our previous
data of immunofluorescence assay showing that ISO
increased the endogenous SPK2 mainly in a cytoplasmic
manner.17 Importantly, ISO greatly increased the colocaliza-
tion of endogenous SPK2 and Bcl-2 in cytoplasm (Figure 5e).
All these results suggest that SPK2 might interact to Bcl-2 in
the cytoplasm of neurons.
Mutation in the putative BH3 domain of SPK2
(SPK2-L219A) prevents autophagy activation. SPK2
contains a 9-amino acid motif found in the sequence of
pro-apoptotic BH3-only proteins, and a Leu219 to Ala
substitution in this sequence was previously shown to
decrease the pro-apoptotic effect of overexpressed mutant
SPK2 (Figure 6a).23 Because some BH3-only proteins (e.g.,
Bad and BNIP3) mediate autophagy by disrupting the
interaction between Beclin-1 and Bcl-2 or Bcl-XL,
25,26 we
then tested the hypothesis that the effect of SPK2 on
autophagy is dependent on its BH3 domain. To do so, we
mutated Leu219 to Ala and use the mutant SPK2 lentivirus to
establish a stable LV-L219A-HT22 cell line. The apoptosis in
the SPK2 overexpressed HT22 cells was examined by
Hoechst staining. The basal apoptotic rate of LV-vector-
Figure 2 SPK2 overexpression induced autophagy activation in cortical neurons. (a) LC3II was upregulated in LV-SPK2-transfected neurons. Neurons were exposed to OGD
for 4 h. After OGD treatment, cortical neurons transfected with LV-vector or LV-SPK2 were harvested and subjected to western blot analysis. (b) Autophagic flux was examined by
comparing LC3II/actin with or without NH4Cl. Neurons were treated with NH4Cl (20 mM) for 24 h. (c and d) 3-MA abolished the neuroprotection induced by SPK2 overexpression.
The neurons were treated with 3-MA (10 mM) for 24 h during OGD reperfusion. Cell counting kit-8 (c) and LDH release (d) was examined to determine cell viability and
cytotoxicity. Bar represents mean± S.D., n= 3 independent experiments. *Po0.05, **Po0.01, ***Po0.001
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HT22 cells is about 1.3%, and there is no significant
difference in apoptotic rate among LV-SPK2-HT22,
LV-L219A-HT22 and LV-vector-HT22 cells, suggesting that
SPK2 overexpression did not induce significant apoptosis in
neural cells (Supplementary Figure S3). Western blot
quantification showed similar SPK1 levels in all cell lines
(Figure 6b), but immunoreactivity for HA-Tag and for SPK2
were significantly higher in both LV-SPK2-HT22 and
LV-L219A-HT22, compared with LV-vector-HT22 and control
cells (Figure 6b). Furthermore, the LC3II was elevated in
LV-SPK2-HT22 cells, but not in LV-L219A-HT22 cells
(Figure 6c). Transmission electron microscope (TEM) was
used to survey the extent of autophagosome formation in LV-
SPK2-HT22 and LV-L219A-HT22 cells. HT22 cells infected
with LV-vector appeared normal with relatively healthy-
looking organelles and nuclei. The organelles and nuclei in
LV-SPK2-HT22 and LV-L219A-HT22 cells also seemed
normal without appreciable injury, but more double-mem-
brane or multi-membrane vacuolar structures were found in
the LV-SPK2-HT22 cells than that in LV-vector-HT22 and
LV-L219A-HT22 cells (Figure 6d), providing morphological
evidence that the putative BH3 domain of SPK2, and more
specifically Leu219, plays an important role in SPK2-induced
autophagy activation.
Tat-SPK2 peptide induces autophagy activation. We
hypothesized that the BH3 domain of SPK2 might be
sufficient to induce autophagy, and designed cell permeable
Tat-SPK2 and Tat-L219A peptides composed of an 18-amino
acid segment encompassing the BH3 domain of wild type or
L219A-mutant SPK2, N-terminally conjugated to biotin46,47
(Figure 6a). By imaging cells stained with Alexa Fluor 488–
streptavidin conjugate, we confirmed that biotin-conjugated
Tat-SPK2 was able to penetrate HT22 cell membranes
(Figure 7a). Treatment with 10 μM Tat-SPK2 peptide, but
not Tat-L219A, increased the LC3II after 1h, indicating that
Tat-SPK2 peptide did activate autophagy (Figure 7b). The
LC3II in the presence versus absence of lysosomal protease
inhibitor NH4Cl increased after Tat-SPK2 treatment at 1 and
3 h (Figure 7c), suggesting that autophagic flux was main-
tained up to 3 h after peptide treatment. The results of TEM
showed that more double-membrane or multi-membrane
vacuolar structures were found in HT22 cells treated with
10 μM Tat-SPK2 peptide for 1 h than in the control group
Figure 3 SPK2 disrupted Beclin-1/Bcl-2 complex to activate autophagy in cortical neurons. (a and b) Beclin-1 knockdown abolished SPK2-induced autophagy activation.
Cortical neurons transfected with LV-vector or LV-SPK2 were further transfected with Beclin-1 siRNA on DIV6. Beclin-1 (a) and LC3 levels (b) were measured by western blotting.
(c) SPK2 disrupted Beclin-1/Bcl-2 complex. Lysates were immunoprecipitated with anti-Bcl-2, separated by SDS-PAGE and subjected to blot analysis with the indicated antibody.
Bar represents mean±S.D., n= 3 independent experiments. *Po0.05. NC, negative control
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instead of Tat-L219A peptide (Figure 7d). All these results
suggested that Tat-SPK2 peptide could activate autophagy.
Tat-SPK2 peptide protects HT22 cells and primary
neurons from OGD injury. We then investigated whether
Tat-SPK2 peptide treatment induced ischemic tolerance in
HT22 cells and primary neurons. In HT22 cells, 10 μM
Tat-SPK2 peptide but not Tat-L219A significantly enhanced
cell viability compared with OGD alone (Figure 8a). Notably,
pretreatment with autophagy inhibitor 3-MA effectively
abolished Tat-SPK2-induced protection (Figure 8b). Atg5 is
a crucial gene involved in autophagosome biogenesis.48,49
Two siRNAs directed against Atg5 were used to inhibit the
induction of autophagy. Atg5 protein was efficiently reduced
by Atg5 siRNAs compared with the negative control (NC).
Knockdown of Atg5 could effectively abolish the neuro-
protection induced by Tat-SPK2, further suggesting autop-
hagy is involved in Tat-SPK2-mediated ischemic tolerance
(Figure 8c). In primary neurons, Tat-SPK2 peptide at
concentrations of 0.01 to 0.1 μM also increased the cell
viability compared with OGD alone or Tat-L219A group
(Figure 8d). All these results suggested that Tat-SPK2
peptide could protect neural cells against OGD injury by
autophagy activation.
Discussion
The goal of the study was to expand on previous findings
showing that SPK2 mediates ischemic tolerance and
autophagy in cerebral preconditioning,17 and to explore the
mechanism underlying autophagy activation induced by
SPK2. There are many measurements to monitor autophagy,
such as monitoring LC3II conversion, autophagy flux, autop-
hagosomes or autolysomes, and detection of Atg proteins or
other signals in the autophagy pathway, etc.50 In this study, we
examined the LC3 levels, determined autophagy flux by using
a lysosome inhibitor and used transmission election micro-
scopy to observe autophagosomes and autolysosomes. In
both primarymurine cortical neurons andHT22 neuronal cells,
SPK2 overexpression was associated with upregulated LC3II
and enhanced autophagy flux. Knockdown of Beclin-1
inhibited SPK2-induced autophagy. SPK2 overexpression
exerted neuroprotection against OGD injury in cortical
neurons, and these effects were suppressed by autophagy
inhibitor 3-MA. Our results indicated that SPK2 can interact
with Bcl-2 via its BH3 domain, leading to the dissociation of
Bcl-2 from Beclin-1 complex and to autophagy activation
(Figure 9). Furthermore, the results of our experiments with
Tat-SPK2 peptide suggested that agents mimicking the BH3
domain of SPK2 might be used therapeutically to induce
autophagy and/or neuroprotection.
SPK2 can be upregulated by various preconditioning stimuli
to mediate neuroprotection against cerebral ischemia11–13
and SPK2-mediated ischemic tolerance seems to involve
autophagy.17 Data in this report confirmed previous findings
and established causality by showing that SPK2 overexpres-
sion led to upregulated LC3II and enhanced autophagy flux,
protected cortical neurons fromOGD injury, whereas 3-MA, an
Figure 4 SPK2 interacts with Bcl-2 in HT22 cells. (a) Stable transfected LV-SPK2-HT22 cell lysates were immune-precipitated with anti-HA, separated by SDS-PAGE, and
subjected to western blot analysis with anti-Bcl-2. (b) Cell lysates were immunoprecipitated with anti-Bcl-2, separated by SDS-PAGE, and subjected to western blot analysis with
anti-HA. (c) GST-Bcl-2 or GST bound to glutathione-agarose, incubated with lysates of LV-HA-SPK2-transfected HT22 cells and subjected to western blot analysis with anti-HA.
n= 3 independent experiments
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autophagy inhibitor, effectively suppressed SPK2 elicited
neuroprotection against OGD. All these results indicated that
SPK2-induced autophagy activation contributes to its
neuroprotection against OGD injury.
We previously hypothesized that SPK2-mediated autop-
hagy during preconditioning was due to disruption of the
interaction between Beclin-1 and Bcl-2, rather than to SPK2
catalytic activity.17 We now tested whether SPK2 overexpres-
sion directly activates autophagy via the Beclin-1 pathway.
Our results showed that knockdown of Beclin-1 effectively
suppressed the autophagy activation by SPK2, and
SPK2 reduced the amount of co-immunoprecipitation of
Beclin-1 and Bcl-2. In addition, both co-immunopreci-
pitation and GST pull-down analysis demonstrated that
SPK2 directly interacted with Bcl-2. These results strongly
suggested that SPK2 disrupts Beclin-1 /Bcl-2 complexes via
its interaction with Bcl-2 to release free Beclin-1 and to activate
autophagy.
Based on sequence analysis, SPK2 contains a 9-amino
acid motif similar to the sequence in BH3-only proteins51
which contribute to cell apoptosis in some cancer cell lines.23
Beclin-1, via its BH3 domain, also interacts with Bcl-2 or
Figure 5 The distribution of SPK2 in the cytoplasm and nuclear fraction of neural cells. (a) LV-vector-HT22 and LV-SPK2-HT22 cells were fixed with 4% paraformaldehyde
and processed for immunofluorescence. Representative images were stained with DAPI (blue) and antibody against SPK2 (red). Scale bar= 10 μm. (b) Nuclei and cytoplasm of
LV-vector-HT22 and LV-SPK2-HT22 cells were extracted and subjected to western blot analysis. (c) Cortical neurons were infected with LV-SPK2 or LV-vector at DIV2. At DIV 7,
the nuclei and cytoplasm of neurons were extracted and subjected to western blot analysis. (d) The distribution of SPK2 in the cytoplasm and nuclear fraction of neurons after
isoflurane preconditioning (ISO). The neurons were exposed to 2% ISO for 30 min. Twenty-four hours later, the cytoplasmic and nuclear fractions of neurons were extracted and
subjected to western blot analysis. (e) ISO increased the colocalization of SPK2 and Bcl-2 in the cytoplasm of neurons. Neurons were fixed with 4% paraformaldehyde and
processed for immunofluorescence. Representative images were stained with DAPI (blue), and antibodies against SPK2 (red) and Bcl-2 (green). Scare bar = 10 μm. n= 3
independent experiments
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Bcl-XL to regulate autophagy.25 Many BH3-only proteins are
mediators of autophagy, since they can disrupt the interaction
between Beclin-1 and Bcl-2/Bcl-XL to activate autophagy
through the BH3 domains.47,52 BNIP3, a BH3 domain-
containing protein, can be upregulated by hypoxia-inducible
factor-1α (HIF-1α) and displace Beclin-1 fromBeclin-1/Bcl-2 or
Beclin-1/Bcl-XL complexes, releasing Beclin-1 and regulating
mitophagy.26,52,53 We thus proposed that SPK2 might activate
autophagy via its BH3 domain by a mechanism similar to
BNIP3. We site directed mutated Leu-219 in the BH3 domain
of SPK2 to Ala (SPK2-L219A) and established stable L219A
transfected HT22 cells.23 The L219A mutation not only
showed reduced level of SPK2 expression, but also revealed
compromised autophagy activity, as the LC3II and the amount
of autophagosomes was obviously less in L219A-HT22 cells
than that in SPK2-HT22 cells. These results implicated that
the autophagy activation by SPK2 is dependent on its BH3
domain.
To further verify the role of SPK2′s BH3 domain in
autophagy activation, we designed a cell permeable Tat-
SPK2 peptide based on the sequence of the putative BH3
domain of SPK2.23,46 Our data confirmed that Tat-SPK2
peptide could enter HT22 cells. As expected, Tat-SPK2
peptide instead of Tat-L219A could upregulate LC3II and
increase the autophagy flux. Importantly, Tat-SPK2 peptide
protected HT22 cells as well as primary neurons against OGD
injury, while inhibition of autophagy effectively abolished
Tat-SPK2-mediated ischemic tolerance. All these results
implied that the BH3 domain of SPK2 is sufficient to activate
autophagy and exert neuroprotection against ischemia.
Although SPK2 inhibits proliferation and enhances apopto-
sis through its BH3 domain in different cell types,23 recent
reports also show that SPK2 plays a role in regulating cancer
cell proliferation and migration54,55 and SPK2 inhibitors may
serve as the therapy for cancers.56 The discrepancy may be
partly due to the expression level57 and cellular distribution of
SPK2 in cells. The intracellular localization of SPK2 varies
Figure 6 SPK2-L219A mutation prevents autophagy activation in HT22 cells. (a) Sequences of SPK2 amino acids 210–227, Tat-SPK2 and Tat-L219A peptide. (b) SPK2 and
SPK1 expression in LV-L219A-HT22 and LV-SPK2-HT22 cells. The control, LV-vector, LV-SPK2 and LV-L219A-HT22 cells were harvested and subjected to western blot analysis.
(c) LC3II was not upregulated in LV-L219A-HT22 as LV-SPK2-HT22 cells. (d) Electron microscopic images show increased number of double-membrane vacuolar structure in the
LV-SPK2-HT22 but not in LV-L219A-HT22 cells. Scale bar= 1 μm. Arrows point to autophagosomes or autolysosomes. N: nucleus. Insets show the enlarged autophagosomes or
autolysosomes taken from the boxed areas. Bar represents mean± S.D., n= 3 independent experiments. *Po0.05, ***Po0.001
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depending on cell types, activation state and/or density.58,59
Although SPK2 is often a nuclear kinase,58–62 various groups
also reported a cytoplasmic and mitochondrial localization of
SPK2.58,60,63–65 In neurons, SPK2 can be expressed in the
cytoplasm, mitochondria and nucleus under physiological or
pathological conditions.41–44 Recent study suggest that over-
expressed SPK2 in nucleus is neurotoxic and promotes DNA
double-strand breaks in cultured primary neurons.44 However,
our data showed that SPK2 was overexpressed in both the
cytoplasm and nuclei of the SPK2 overexpressed neurons and
HT22 cells. On the other hand, Bcl-2 was mainly expressed in
the cytoplasm of both LV-SPK2-HT22 cells and SPK2-
overexpressing neurons. Importantly, ISO and hypoxic pre-
conditioning, a noxious stimulus that could be applied
conveniently to elicit neuroprotection in vivo and in vitro, could
upregulate endogenous SPK2 to activate autophagy.17 ISO
seems to increase the colocalization of endogenous SPK2
and Bcl-2 mainly in a cytoplasmic manner. From all these
results, we assume that SPK2 might interact to Bcl-2 in the
cytoplasm to activate autophagy. It remains to be elucidated
whether the different distribution of SPK2 contributes to
different signaling regulating autophagy and cell survival.
Our results are supported by several studies showing that
mild endogenous SPK2 activation is one of the protective
Figure 7 Tat-SPK2 peptide-induced autophagy in HT22 cells. (a) Intracellular staining pattern of biotin-conjugated Tat-SPK2 peptide. HT22 cells were treated with 10 μM Tat-
SPK2 or vehicle for 6 h, and stained with Alexa Flour 488-conjugated streptavidin. Scale bar= 10 μm. (b) Tat-SPK2 but not Tat-L219A upregulated LC3II. HT22 cells were treated
with 10 μM Tat-SPK2 or Tat-L219A peptide for indicated time. Then the cells were harvested and subjected to western blot analysis. (c) Autophagic flux was examined by
comparing LC3II/actin with or without NH4Cl. HT22 cells were treated with 10 μM Tat-SPK2 for indicated time, and then treated with 20 mM NH4Cl for 24 h. (d) Electron
microscopic images show increased number of double-membrane vacuolar structure in HT22 cells treated with 10 μM Tat-SPK2 peptide for 1 h but not in Tat-L219A peptide-
treated HT22 cells. Scale bar= 0.5 μm. Arrows point to autophagosomes or autolysosomes. N: nucleus. Insets show the enlarged autophagosomes or autolysosomes taken from
the boxed areas. Bar represents mean± S.D., n= 3 independent experiments. *Po0.05, **Po0.01, ***Po0.001
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mechanisms in both cerebral ischemia and myocardial
ischemia.66,67 SPK2-mediated mechanism is involved in the
protective effects of allicin against cerebral ischemia
both in vivo and in vitro.68 SPK2 also contributes to the
ischemic tolerance induced by cerebral or myocardial
preconditioning.11,12,13,67,69 Overexpressed SPK2 in cardio-
myocyte effectively inhibits apoptosis induced by hypoxia/
reoxygenation.69 In agreement with these reports, no sig-
nificant apoptosis was observed in SPK2-transfected HT22
cells in this study. Instead, SPK2 overexpression and
Tat-SPK2 peptide containing BH3 domain of SPK2 protected
neurons from OGD injury. In fact, BH3 domain has dual
functions in apoptosis and autophagy.47,52 BH3 proteins like
Beclin-125,70,71 and BNIP324 contributes to survival rather than
apoptosis under certain conditions, such as nutrient
deprivation and hypoxia. The BH3 domains of hypoxia-
induced BNIP3/BNIP3L could induce autophagy and cell
survival by disrupting the Bcl-2/Beclin1complex without
inducing cell death.24 We thus propose that SPK2, like low-
affinity BH3 binding partners BNIP3 and Beclin-1, will not
trigger cell death during hypoxia, possibly because the
interaction between SPK2 and Bcl-2 is too weak in compar-
ison with those of BAD or BIM to trigger apoptosis.72 On the
other hand, it was reported that high-level overexpression of
SPK2 inhibits cell survival and proliferation, while low-level
overexpression of SPK2 promotes cell survival and
proliferation.57 Thus the low level of SPK2 overexpression
achieved in the present study (about twofold versus control) is
similar to the effect of preconditioning to induce cell survival
and protection.17 Furthermore, the dose of Tat-SPK2 peptide
Figure 8 Tat-SPK2 peptide protected neural cells from OGD injury. (a) Tat-SPK2 peptide protected HT22 cells from OGD injury. HT22 cells were treated with Tat-SPK2 or
Tat-L219A peptide at the indicated concentrations for 1 h, and then were exposed to oxygen glucose deprivation (OGD) for 6 h. The cell viability was examined by cell counting
kit-8 assay. (b) 3-MA abolished Tat-SPK2-induced neuroprotection. Cells were treated with 10 μM Tat-SPK2 or Tat-L219A peptide for 1 h, and then were exposed to OGD for 6h.
Cells were treated with 2.5 mM 3-MA for 12 h during reperfusion. (c) Atg5 knockdown abolished Tat-SPK2-induced protection. HT22 cells were transfected with Atg5 siRNA using
lipofectamine 2000. Atg5 was measured by western blotting. Seventy-two hours after transfection, cells were treated with 10 μM Tat-SPK2 or Tat-L219A peptide for 1 h, and then
were exposed to OGD for 6 h. (d) Tat-SPK2 peptide protected primary neurons from OGD injury. Primary neurons were treated with Tat-SPK2 or Tat-L219A peptide at the
indicated concentrations for 3 h, and then were exposed to OGD for 4 h. Bar represents mean± S.D., n= 3. *Po0.05, **Po0.01, ***Po0.001. NC, negative control
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is also an important factor, as the lower dose of Tat-SPK2
might show stronger neuroprotection compared with higher
dose. Tat-SPK2 peptide of 5.8–10 μM in HT22 cells and 0.01–
0.1 μM in primary neurons showed a significant neuropotec-
tion against OGD injury. However, the higher dose of Tat-SPK2
(13.3 μM in HT22 cells and 0.3 μM in neurons) does not show
changes compared with the L219A peptide. Tat-SPK2 peptide
even shows toxicity at the dose over 20 μM in HT22 cells and
over 5 μM in primary neurons (data not shown). All these
results further support the notion that expression level of SPK2
is important for its function.
In conclusion, our present results demonstrated that SPK2
could activate autophagy to protect neurons from OGD injury.
SPK2, via its BH3 domain, could dissociate Beclin-1/Bcl-2
complex by interacting with Bcl-2 to activate autophagy. Tat-
SPK2 peptide designed from the BH3 domain of SPK2 could
activate autophagy and protect neurons against OGD injury.
SPK2 and Tat-SPK2 peptide promote neuronal survival
through induction of autophagy, implying that SPK2 inducers,
Tat-SPK2 peptide or agents acting on Beclin-1/autophagy
pathway may provide candidate therapeutic agents against
ischemic stroke. Further studies are required to investigate
whether Tat-SPK2 peptide is effective in animal models of
ischemic stroke.
Materials and Methods
Cell culture. Primary cultured murine cortical neurons were prepared from the
cortex of E15–17 mouse embryos.15,17 Briefly, timed pregnant mice (Center of
Experimental Animals of Soochow University, certificate No 20020008, Grade II)
were killed by decapitation under 2% isoflurane. Cortices from embryos were
dissected into pre-cooled PBS, and then digested in 1.25% trypsin at 37 °C for
15 min. The trypsin digestion was stopped by DMEM (Gibco) with 10% fetal bovine
serum (FBS; Gibco, Waltham, MA, USA) and the cell suspension was treated with
DNase I (Sangon Biotech, Shanghai, China) for 3 min. The cells were centrifuged at
500 × g for 5 min, and the supernatant was removed. The pellets were resuspended
with neurobasal medium (NBM; Gibco) with 10% B27 (Gibco) and 25 μM glutamate
(Sigma, St. Louis, MO, USA). After filtration through 40 μm strainer, cells were plated
on 0.1 mg/ml poly D-lysine (Sigma)-coated six-well (6 × 105 cell/well) or 24-well
(1.0 × 105 cell/well) dishes. The medium was changed to NBM with 10% B27 and
0.5 mM glutamine (Sangon Biotech), 1% penicillin G and streptomycin after 24 h. Half
the medium was changed every 2 days. Cortical neurons were used for experiments
after 7–10 days in vitro.
HT22 mouse hippocampal neuronal cells were obtained from Shanghai Institute of
Cell Biology (Shanghai, China). Cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Gibco) supplemented with 10% FBS (Gibco), 100 U/ml
streptomycin, 100 U/ml penicillin at 37 °C in 5% CO2/95% air.
Lentivirus-mediated SPK2 overexpression. LV-SPK2 mouse-EGFP-
HA-Puro (5 × 108 TU/ml, GENEID 308589, NM020011) lentivirus was constructed by
Shanghai Genechem Co. Ltd (Shanghai, China). On the second day in vitro (DIV2),
cortical neurons were switched to NBM containing 10% B27, 0.5 mM glutamine and
LV-SPK2 (MOI= 10) or LV-vector (VEC) for 24 h. Afterwards, the medium was changed
to the regular medium.73 The GFP immunofluoresence was observed at 7 days after
transfection with a fluorescence microscope (Olympus; IX71, Tokyo, Japan).
To establish stably infected HT22 cells, the HT22 cells were infected with LV-SPK2
mouse-EGFP-HA-Puro, LV-SPK2-L219A mouse-EGFP-HA-Puro lentivirus
(5 × 108 TU/ml, HA-NM020011-mu1; Genechem, Shanghai, China) or LV-vector
(MOI= 10) for 24 h. Afterwards, the medium was changed to regular medium for
24 h. Cells were then selected with 2 μg/ml puromycin (Sigma) for 2 weeks.74 The
stable SPK2 or L219A infected HT22 cells were identified using GFP expression and
western blot analysis.
Oxygen glucose deprivation. Primary cultured cortical neurons or HT22
cells were washed three times with Hepes balanced salt solution (HBSS: NaCl
140 mM, KCl 3.5 mM, CaCl2 1.7 mM, MgSO4 12 mM, KH2PO4 0.4 mM, NaHCO3
5 mM, Hepes 10 mM; pH 7.2–7.4). Cultures were placed in a chamber (Billups-
Rothenberg MC-101) filled with 95% N2 and 5% CO2 at 37 °C for 4 h (cortical
neurons) or 6 h (HT22 cells). Upon removal of the cultures from the chamber, the
growth medium was changed back to normal medium.16
ISO model. Primary culture cortical neurons were exposed to 2% isoflurane (RWD
Life Science, Shenzhen, China, R510–22, in 70% nitrogen and 30% oxygen) at 37 °C
for 30 min in an airtight chamber. The neurons were handled 24 hours later.17
Cell viability assay. Cell Counting Kit-8 (CCK8; Dojindo Laboratories, Tokyo,
Japan) or LDH (Beyotime, Shanghai, China) assay was used to determine cell
viability. For CCK8 assay, 24 h after OGD, 10 μl CCK8 was added into each well of
96-well plates, which were incubated at 37 °C for 2 h. Optical density was measured
at 450 nm using a plate reader (ELX 800; Bio-Tek, Winooski, VT, USA). For LDH
assay, the neurons and culture medium were lysed in PBS containing 1% Triton
X-100 at 37 °C for 30 min, respectively. The LDH activities in both the cell lysates
and the culture mediums were assayed with the assay kit following the
manufacturer’s instructions. LDH leakage was calculated as follows: LDH leakage
(%)= LDH culture medium/(LDH culture medium+LDH cell lysates) × 100%.73
Sphingosine kinase 2 activity assay. SPK2 activity was determined using
the fluorescent substrate NBD-sphingosine (avanti Polar Lipids; 810205P).12,75 HT22
cells were collected in lysis buffer (Hepes 50 mM, pH 7.4, KCl 10 mM, glycerol 20%,
dithiothreitol 2 mM, NaF 15 mM, semicarbazide 2 mM, EDTA-free complete protease
inhibitor (Roche, Basel, Switzerland)). Twenty-five micrograms of lysate protein
reacted with reaction mixture (Hepes 50 mM, pH 7.4, MgCl2 15 mM, glycerol 10%,
ATP 10 mM, NaF 15 mM, semicarbazide 2 mM, NBD-sphingosine 10 μM and KCl
1 M (for SPK2 specificity12)). After 1 h, the reaction was stopped by 50 μl 1 M K3PO4
(pH 8.5). Then 250 μl CHCl3/CH3OH (2:1) was added and the lysates were
centrifuged at 15000× g for 1 min. One hundred microliters upper aqueous phase
was incubated with 50 μl dimethylformamide and NBD fluorescence was read by
Multiskan Spectrum Microplate Reader (TECAN Infinite M1000 Pro, Mannedorf,
Siwtzerland), excitation at 485 nm, emission at 538 nm).
Western blot analysis. Cells were rinsed twice with cooled PBS and lysed in
a buffer containing Tris-HCl (pH 7.4) 10 mM, NaCl 150 mM, 1% Triton X-100, 1%
sodium dexoxycholate, 0.1% SDS, EDTA 5 mM and EDTA-free complete protease
inhibitor (Roche). Protein concentrations were determined by BCA assay. Equal
amounts (10–30 μg) of total protein extracts were separated by SDS-PAGE and
transferred to nitrocellulose membranes. Western blot analysis was used to measure
the levels of SPK2 (1 : 200; Abgent, San Diego, CA, USA, AP7238a),
HA-Tag (1:1000; CST3724S), SPK1 (1 : 1000, Abgent AP7237c), LC3 (1 : 1000;
Abcam, Cambridge, UK, ab62721), Beclin-1 (1 : 1000, Santa Cruz, Dallas, TX, USA,
sc-11427). Expression levels were normalized to β-actin (1 : 10000; Sigma A5441).
Figure 9 Proposed mechanism underlying autophagy activation induced by SPK2.
Under normal conditions, Beclin-1 interacts with Bcl-2 via its BH3 domain to decrease
the autophagy activity. Overexpression of SPK2may displace Beclin-1 from Bcl-2 via its
BH3 domain, leading to release of Beclin-1 and autophagy activation. Tat-SPK2 peptide
containing BH3 domain of SPK2 might also bind to Bcl-2, and hence disrupt the
interaction between Bcl-2 and Beclin-1 to induce autophagy. Autophagy then
contributes to the neuroprotection induced by SPK2 or Tat-SPK2 peptide
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Hoechst staining. Cells were fixed with 4% paraformaldehyde for 15 min and
the nuclei were stained with Hoechst 33342 for 15 min. Fluorescence was observed
with a fluorescence microscope (Olympus, IX71). Cells undergoing apoptosis were
characterized by brightly stained, condensed nuclei. The percentages of apoptotic
cells were counted in four random fields.
SPK2 and/or bcl-2 immunofluorescence. Cells were fixed with 4%
paraformaldehyde for 15 min and incubated with PBS containing 0.1% Triton X-100
for 30 min. After blocking with 1% BSA for 1 h, cells were incubated with antibodies
against SPK2 (1:100) and/or Bcl-2(1:20; Santa Cruz sc-7382) at 4 °C for 24 h, and
with anti-rabbit IgG(H+L) secondary antibody, Dylight 633 (1:500; Invitrogen) and/or
anti-mouse IgG (H+L) secondary antibody, DyLight 488 (1:500; Invitrogen) for 2 h.
Then the cells were stained with DAPI (1:10000; sigma D9564) for 10 min. Images
of fluorescence were acquired using a laser scanning confocal microscopy (ZEISS
LSM710, Oberkochen, Germany).17
Nuclear extraction. Cells were centrifuged at 1500 × g for 5 min at 4 °C and
lysed in buffer A (sucrose 1 M, CaCl2 0.1 M, MgAc 1M, EDTA, DTT 100 nM, NP40
0.5%, EDTA-free complete protease inhibitor (Roche)). The lysates were then
centrifuged at 600 × g for 15 min to separate the cytoplasmic fraction of the cell
extract. The pellets were resuspended in buffer B (sucrose 1 M, CaCl2 0.1 M, MgAc
1 M, EDTA 250 mM, DTT 100 nM), and centrifuged at 600 × g for 10 min. The
pellets were taken as the nuclear fraction.76 Lamin B (Santa Cruz sc6216) and
GAPDH (Abcam, ab8245) were used as nuclear and cytoplasmic markers.
Co-immunoprecipitation. Cells were harvested and lysed in a buffer
containing Tris-HCl 50 mM (pH 7.4), NaCl 150 mM, 0.05% sodium deoxycholate,
1% NP40 and EDTA-free complete protease inhibitor (Roche). The lysates were
precleaned with protein G-agarose (Roche) for 1 h, incubated with antibody (Bcl-2,
Santa Cruz sc-7382; HA-Tag, CST3724S) or IgG (normal mouse IgG, Santa Cruz
sc-2025, normal rabbit IgG, Santa Cruz sc-2027) overnight. After washing away
unbound antibody, lysates were incubated with protein G-agarose for 4–8 h.17 The
immunoprecipitates were analyzed by western blotting using antibody against HA,
Bcl-2 (Santa Cruz sc-492) or Beclin-1.
GST pull-down. Glutathione-agarose (Santa Cruz sc-2009) beads were
washed with 1% Triton X-100 PBS, and were incubated with GST (Flarebio,
Wuhan, China, CSB-RP101744Ba) or Bcl-2 GST fusion protein (PTG, Wuhan,
China, ag3508) for 1 h at 4 °C under constant mixing. After washing away unbound
proteins three times with pre-cooled lysis buffer, the GST-bead complex was
incubated overnight with cell lysates.77 The bound proteins eluted from the beads
were subjected to western blot analysis using anti-HA or anti GST antibody
(1 : 1000, Santa Cruz sc-138).78
Electron microscopy. HT22 Cells were harvested and fixed in 2.5%
gluteraldehyde in 0.1 M phosphate buffer (pH 7.4) at 4 °C. The cell pellets were
post-fixed with 1% Osmium tetroxide, dehydrated through acetone and then
immersed in resin. After hardening, the blocks were sectioned at 50 nm thickness
and stained with lead citrate. Then the autophagosomes or antolysosomes were
viewed on a Transmission Electron Microscope (JEOL JEM 1230,Tokyo, Japan).
Autophagosomes were defined as double- or multiple-membrane structures
surrounding cytoplasmic constituents, while autolysosomes were defined as single
membrane structures containing cytoplasmic components.79 At least 10 fields of
view of each sample were captured. Three independent experiments with different
samples were analyzed.
Peptide synthesis and treatment. Tat-SPK2 peptide and Tat-L219A
peptide (Figure 6a) were synthesized by Chinese Peptide Company (Hangzhou,
China, purity 95%). Tat-SPK2 peptide sequence consisted of 11 amino acids from
the Tat protein transduction domain (PTD),46 a GG linker, and the 18 amino acids
derived from the SPK2 210–227.23 The control peptide, Tat-L219A, consisted of
PTD, a GG linker and 18 amino acids of SPK2 210–227 containing one substitution,
L219A. The Tat-SPK2 and Tat-L219A peptides were dissolved in double distilled
water and then diluted to the working solution with complete medium. To determine
the autophagy activity, HT22 cells were pretreated with the peptides at 10 μM for
1–6 h. For cell viability analysis, HT22 cells were pretreated with the peptides at the
indicated concentrations for 1 h before OGD and during the whole OGD period.
Primary neurons were pretreated with the peptides for 3 h, and then exposed to
OGD for 4 h. The peptide was removed during OGD episode.
Peptide entry assay. HT22 cells were treated with 10 μM biotinylated
Tat-SPK2 for 6 h. Cells were fixed with 4% paraformaldehyde for 10 min at room
temperature. Then HT22 cells were permeabilized with 0.1% Triton X-100 and
stained with Alexa Fluor 488-conjugated streptavidin for 1 h.47 Fluorescence was
observed by a laser scanning confocal microscope (ZEISS LSM710).
Drug treatment. Cortical neurons or HT22 cells were treated with autophagy
inhibitor (Sigma; M9281) for 12–24 h following OGD.16,34,36 Neurons or HT22 cells
were treated with an lysosomal inhibitor NH4Cl (Greagent G17391B) 20 mM for 24
h.32,33,74
siRNA. Small-interfering RNAs against Beclin-1 (siRNA1, sense: 5′-GGAGU
GGAAUGAAAUCAAUTT-3′, antisense: 5′-AUUGA -UUUCAUUCCACUCCTT-3′;
siRNA 2, sense: 5′-GAUCCUGG -ACCGGGUCACCTT-3′, antisense: 5′-GGUGAC
CCGGUCCAGGAUCTT-3′)17 or Atg5 (siRNA1, sense: 5′-GCGGUUGAGGCUC
ACUUUATT-3′, antisense: 5′-UAAAGUGAGCCUCAACCGCTT-3; siRNA 2, sense:
5′-CCAUCAACCGGAAACUCAUTT-3′, antisense: 5'-AUGAGUUUCCGGUUGAU
GGTT-3′) were synthesized by Genepharma (Shanghai, China). Transfection of
Beclin-1 siRNA (40 nM) in cortical neurons was performed using lipofectamine 2000
(Invitrogen) on day 6 in vitro (DIV6)80 according to the manufacturer’s instructions.
HT22 cells were transfected with Atg5 siRNA (80nm) using lipofectamine 2000. The
cells were also transfected with a control scrambled RNA targeting a sequence not
sharing homology with the Mus Musculus Genome (negative control, NC). The
suppression of Beclin-1 or Atg5 expression was confirmed with western blotting.
Statistical analysis. The data were expressed as mean± S.D. The
significance between groups was determined with one-way ANOVA, followed by
the Newman–Keuls test for post hoc analysis.
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